Reagan-Udall Post-Market Drug Surveillance Initiative Could Address Patient Web Sites
This article was originally published in The Pink Sheet Daily
The IMEDS project getting under way at the Reagan-Udall Foundation could eventually address methods for analyzing data on drug side effects that are available through patient networking sites and blogs, though initial efforts will focus on insurance claims data and electronic medical records.
You may also be interested in...
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.